Esperion Therapeutics traded at $3.43 this Wednesday February 11th, increasing $0.04 or 1.03 percent since the previous trading session. Looking back, over the last four weeks, Esperion Therapeutics gained 3.52 percent. Over the last 12 months, its price rose by 82.18 percent. Looking ahead, we forecast Esperion Therapeutics to be priced at 2.70 by the end of this quarter and at 2.46 in one year, according to Trading Economics global macro models projections and analysts expectations.
Esperion Therapeutics, Inc. is a lipid management company. The Company is a pharmaceutical company focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its bempedoic acid and the bempedoic acid / ezetimibe combination tablets are oral, once-daily, non-statin, LDL-C lowering medicines for patients with atherosclerotic cardiovascular disease (ASCVD), or heterozygous familial hypercholesterolemia (HeFH). Its products include NEXLETOL, NILEMDO, NEXLIZET and NUSTENDI. NEXLETOL and NILEMDO are ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. NEXLIZET and NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.